Catalent, Inc. (NYSE:CTLT) Holdings Increased by Alpine Associates Management Inc.

Alpine Associates Management Inc. lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 3.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,131,126 shares of the company’s stock after buying an additional 69,875 shares during the quarter. Catalent makes up about 5.9% of Alpine Associates Management Inc.’s holdings, making the stock its 4th biggest holding. Alpine Associates Management Inc.’s holdings in Catalent were worth $129,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Catalent during the 3rd quarter valued at about $276,000. Quest Partners LLC grew its position in Catalent by 289.8% during the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock valued at $2,986,000 after purchasing an additional 36,652 shares during the last quarter. Natixis Advisors LLC purchased a new stake in Catalent during the 3rd quarter valued at about $1,287,000. Mizuho Markets Americas LLC purchased a new stake in Catalent during the 3rd quarter valued at about $30,285,000. Finally, CIBC Asset Management Inc grew its position in Catalent by 7.9% during the 3rd quarter. CIBC Asset Management Inc now owns 25,173 shares of the company’s stock valued at $1,525,000 after purchasing an additional 1,846 shares during the last quarter.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 in the last quarter. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CTLT. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research note on Thursday, November 14th. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Price Performance

Shares of NYSE:CTLT opened at $58.85 on Wednesday. The firm’s 50 day moving average price is $59.80 and its 200-day moving average price is $58.25. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $10.68 billion, a PE ratio of -26.04, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company earned ($0.10) EPS. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. Equities research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.